Cargando…
Cognitive Dysfunction in the Early Stages of Multiple Sclerosis—How Much and How Important?
PURPOSE OF REVIEW: Multiple sclerosis (MS) is a demyelinating disease of the central nervous system that mainly affects young adults and that is one of the leading causes of disability in this age group, with cognitive impairment occurring early in the course of the disease. This article summarizes...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7244611/ https://www.ncbi.nlm.nih.gov/pubmed/32444997 http://dx.doi.org/10.1007/s11910-020-01045-3 |
_version_ | 1783537611282841600 |
---|---|
author | Oset, Magdalena Stasiolek, Mariusz Matysiak, Mariola |
author_facet | Oset, Magdalena Stasiolek, Mariusz Matysiak, Mariola |
author_sort | Oset, Magdalena |
collection | PubMed |
description | PURPOSE OF REVIEW: Multiple sclerosis (MS) is a demyelinating disease of the central nervous system that mainly affects young adults and that is one of the leading causes of disability in this age group, with cognitive impairment occurring early in the course of the disease. This article summarizes the current knowledge about cognitive dysfunction in the early phase of MS, including biomarkers, MRI correlates, and its value as a prognostic marker. RECENT FINDINGS: New sets of neuropsychological tests have been established to screen for cognitive dysfunction more easily and accurately. Moreover, structural changes detected by brain MRI and several biomarkers found in cerebrospinal fluid and blood serum have been recently correlated with decreased cognitive performance. Additionally, factors influencing cognition in MS, such as disease-modifying therapy, mood disorders, and lifestyle, are better described. SUMMARY: Cognitive impairment early in the course of MS is suggested as a prognostic factor for disease progression. However, clear-cut definitions of the early stage of MS as well as unified criteria for the diagnosis of cognitive impairment are still lacking. New and more reliable tools for evaluating cognition in MS patients should be developed and introduced into everyday practice to facilitate the implementation of effective disease-modifying therapy, cognitive rehabilitation, and lifestyle management. |
format | Online Article Text |
id | pubmed-7244611 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Springer US |
record_format | MEDLINE/PubMed |
spelling | pubmed-72446112020-06-03 Cognitive Dysfunction in the Early Stages of Multiple Sclerosis—How Much and How Important? Oset, Magdalena Stasiolek, Mariusz Matysiak, Mariola Curr Neurol Neurosci Rep Demyelinating Disorders (J. Bernard and M. Cameron, Section Editor) PURPOSE OF REVIEW: Multiple sclerosis (MS) is a demyelinating disease of the central nervous system that mainly affects young adults and that is one of the leading causes of disability in this age group, with cognitive impairment occurring early in the course of the disease. This article summarizes the current knowledge about cognitive dysfunction in the early phase of MS, including biomarkers, MRI correlates, and its value as a prognostic marker. RECENT FINDINGS: New sets of neuropsychological tests have been established to screen for cognitive dysfunction more easily and accurately. Moreover, structural changes detected by brain MRI and several biomarkers found in cerebrospinal fluid and blood serum have been recently correlated with decreased cognitive performance. Additionally, factors influencing cognition in MS, such as disease-modifying therapy, mood disorders, and lifestyle, are better described. SUMMARY: Cognitive impairment early in the course of MS is suggested as a prognostic factor for disease progression. However, clear-cut definitions of the early stage of MS as well as unified criteria for the diagnosis of cognitive impairment are still lacking. New and more reliable tools for evaluating cognition in MS patients should be developed and introduced into everyday practice to facilitate the implementation of effective disease-modifying therapy, cognitive rehabilitation, and lifestyle management. Springer US 2020-05-22 2020 /pmc/articles/PMC7244611/ /pubmed/32444997 http://dx.doi.org/10.1007/s11910-020-01045-3 Text en © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Demyelinating Disorders (J. Bernard and M. Cameron, Section Editor) Oset, Magdalena Stasiolek, Mariusz Matysiak, Mariola Cognitive Dysfunction in the Early Stages of Multiple Sclerosis—How Much and How Important? |
title | Cognitive Dysfunction in the Early Stages of Multiple Sclerosis—How Much and How Important? |
title_full | Cognitive Dysfunction in the Early Stages of Multiple Sclerosis—How Much and How Important? |
title_fullStr | Cognitive Dysfunction in the Early Stages of Multiple Sclerosis—How Much and How Important? |
title_full_unstemmed | Cognitive Dysfunction in the Early Stages of Multiple Sclerosis—How Much and How Important? |
title_short | Cognitive Dysfunction in the Early Stages of Multiple Sclerosis—How Much and How Important? |
title_sort | cognitive dysfunction in the early stages of multiple sclerosis—how much and how important? |
topic | Demyelinating Disorders (J. Bernard and M. Cameron, Section Editor) |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7244611/ https://www.ncbi.nlm.nih.gov/pubmed/32444997 http://dx.doi.org/10.1007/s11910-020-01045-3 |
work_keys_str_mv | AT osetmagdalena cognitivedysfunctionintheearlystagesofmultiplesclerosishowmuchandhowimportant AT stasiolekmariusz cognitivedysfunctionintheearlystagesofmultiplesclerosishowmuchandhowimportant AT matysiakmariola cognitivedysfunctionintheearlystagesofmultiplesclerosishowmuchandhowimportant |